Amifostine Does Not Inhibit the Toxic Effects of Anthracycline Derivates or Mitoxantrone on MDR Tumor Cell Lines

References

• Michieli M., Damiani D., Ermacora A., Raspadori D., Michelutti A., Grimaz S., Fanin R., Russo D., Lauria F., Masolini P., Baccarani M. P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells. British Journal of Haematology 1997; 96: 356–365
   PubMed Web of Science ®Google Scholar
• Michieli M., Damiani D., Michelutti A., Grimaz S., Geromin A., Fanin R., Russo D., Masolini P., Baccarani M. Screening for multidrug resistance in leukemia: cell reactivity to MRK16 correlates with anthracyclines retention and sensitivity of leukemic cells. Leukemia and Lymphoma 1996; 18: 179–184
   Google Scholar
• Leith C., Kopecky K. J., Godwin J., McConnell T., Slovak M. L., Chen I. M., Head D. R., Appelbaun E. R., William C. L. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood 1997; 89: 3323–3329
   PubMed Web of Science ®Google Scholar
• Damiani D., Michieli M., Ermacora A., Candoni A., Raspadori D., Geromin A., Stocchi R., Grimaz S., Masolini P., Michelutti A., Scheper R. J., Baccarani M. P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias. Haematologica 1998; 83: 290–297
   PubMed Web of Science ®Google Scholar
• Michieli M., Damiani D., Ermacora A., Masolini P., Raspadori D., Visani G., Scheper R. J., Baccarani M. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukemias: biological and clinical implications. British Journal of Haematology 1999; 104: 328–335
   PubMed Web of Science ®Google Scholar
• Michieli M., Damiani D., Michelutti Candoni A., Masolini P., Scaggiante B., Quadrifoglio F., Baccarani M. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833. Haematologica 1994; 79: 500–507
   PubMed Web of Science ®Google Scholar
• List A. F., Spier C., Greer J., Wolff S., Hutter J., Dorr R., Salmon S., Futscher B., Baier M., Dalton W. Phase I/II trial of cyclosporine as a chemotherapy resistance modifier in acute leukemia. Journal of Clinical Oncology 1994; 11: 1652–1660
   Web of Science ®Google Scholar
• Damiani D., Michieli M., Ermacora A., Russo D., Fanin R., Zaja F, Baraldo M., Pea F., Furlanut M., Baccarani M. Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. Leukemia 1998; 12: 1236–1240
   PubMed Web of Science ®Google Scholar
• Gill P. S., Espina B. M., Muggia F, Cabriales S., Tupule A., Esplin J. A., Liebman H. A., Forssen E. A., Ross M. E., Levine A. M. Phase I/II clinical and pharamcokinetic evaluation of liposomal daunorubicin. Journal of Clinical Oncology 1995; 13: 996–1003
   PubMed Web of Science ®Google Scholar
• Michieli M., Damiani D., Ermacora A., Masolini P., Michelutti A., Michelutti T., Russo D., Pea F., Baccarani M. Liposome encapsulated Daunorubicin for PGP-related multidrug resistance. British Journal of Haematology 1999; 106: 92–99
   PubMed Web of Science ®Google Scholar
• Yuhas J. M., Spellman J. M., Culo F. The role of WR-2721 in radiotherapy and or chemotherapy. Cancer Clinical Trials 1980; 3: 211–216
   PubMedGoogle Scholar
• Capizzi R. L. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Seminars in Oncology 1996; 23: 2–17
   PubMed Web of Science ®Google Scholar
• Alberts D. S., Speicher L. A., Krutzsch M., Wymer J., Capizzi R. L., Conlon J., Barrett A., Aickin M. WR-1065, the active metabolite of amifostine (ethiol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells. European Journal of Cancer 1996; 32A: S17–S20, suppl. 4
   PubMed Web of Science ®Google Scholar
• Taylor C. W., Wang L. M., List A. F., Fernandes D., Paine-Murrieta G. D., Johnson C. S., Capizzi R. L. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. European Journal of Cancer 1997; 33: 1693–1698
   PubMed Web of Science ®Google Scholar
• Fulda S., Oster W., Berthold F. Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro. Anticancer Drugs 1997; 8: 34–41
   PubMed Web of Science ®Google Scholar
• Michieli M., Damiani D., Michelutti A., Melli C., Russo D., Fanin R., Baccarani M. P170-dependent multidrug resistance. Restoring full sensitivity to idarubicin with verapamil and cyclosporin A derivatives. Haematologica 1994; 79: 119–126
   PubMed Web of Science ®Google Scholar
• Russo D., Marie J. P., Zhou D. C., Faussat A. M., Melli C., Damiani D., Michelutti A., Michieli M., Fanin R., Baccarani M., Zittoun R. Evaluation of the clinical relavance of the anionic glutathione-s-transferase (GSTπ) and multidrug resistance (mdr-1) gene coexpression in leukemias and lymphomas. Leukemia and Lymphoma 1994; 15: 453–468
   PubMed Web of Science ®Google Scholar
• Michieli M., Michelutti A., Damini D., Pipan C., Raspadori D., Lauria F., Baccarani M. A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives. Leukemia and Lymphoma 1993; 9: 255–264
   PubMed Web of Science ®Google Scholar
• Kuiper C. M., Broxterman H. J., Baas F., Schuurhuis G. J., Haisma H. J., Scheffer G. L., Lankelma J., Pinedo H. M. Drug transport variant without P-glycoprotein overex-pression from a human squamous lung cancer cell line after selection with doxorubicin. Journal of Cellular Pharmacology 1990; 1: 35–41
   Google Scholar
• Versantvoort C. H.M., Withoff S., Broxterman H. J., Kuiper C. M., Scheper R. J., Mulder N. H., de Vries E. G.E. resistance-associated factors in human small-cell lung carcinoma GLC4 sublines with increasing adriamycin resistance. International Journal of Cancer 1995; 61: 375–380
   PubMed Web of Science ®Google Scholar
• Yuhas J. M. Differential protection of normal and malignant tissues against the cytotoxic effects of mechlo-rethamine. Cancer Treatment Reports 1979; 63: 971–976
   PubMedGoogle Scholar
• Yuhas J. M., Culo F. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum (II) by WR-2721 without altering its antitumour properties. Cancer Treatment Reports 1980; 64: 57–54
   PubMedGoogle Scholar
• List A. F., Heaton R., Glinsman-Gibson B. Amifostine protects primitive human hematopoietic progenitors against cytotoxicity from diverse antineoplastics. In Proceedings of the American Society of Clinical Oncology 1996; 15: 448
   Google Scholar
• Capizzi R. L. The preclinical basis for broad spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Seminars in Oncology 1999; 26: 3–21, suppl. 7
   PubMed Web of Science ®Google Scholar
• Hart S. M., Ganeshaguru K., Hoffbrand A. V., Prentice H. C., Metha A. B. Expression of the multidrug resistance-associated protein (MRP) in acute leukemia. Leukemia 1994; 8: 2163–2168
   PubMed Web of Science ®Google Scholar
• te Boekhorst P. A.W., Löwenberg B., van Kapel J., Nooter K., Sonneveld P. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia 1995; 9: 1025–1031
   PubMed Web of Science ®Google Scholar
• List A. F., Spier C. S., Grogan T. M., Johnson C., Roe D. J., Greer J. P., Wolff S. N., Broxterman H. J., Scheffer G. L., Scheper R. J., Dalton W. S. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996; 87: 2464–2469
   PubMed Web of Science ®Google Scholar
• De Vries E. G.E., Van Luyn M. J.A., Renes J., Meijer C., Scheper R. J., Nienhuis E. F., Mulder N. H., Jansen P. L.M., Müller M. Glutathione conjugate transport in intracellular vesicles in the doxorubicin resistant human lung carcinoma cell line GLC4-Adr is MRP mediated. In Proceedings of the American Association for Cancer Research 1996; 37: 306–312
   Google Scholar
• Renes J., De Vries E. G.E., Nienhuis E. F., Jansen P. L., Muller M. ATP- and glutathione-dependent transport of chmotherapeutic drugs by the multidrug resistance protein MRP1. British Journal of Pharmacology 1999; 126: 681–688
   PubMed Web of Science ®Google Scholar